Treatment(s) now being considered-Radiation Posts on Medivizor
Navigation Menu

Treatment(s) now being considered-Radiation Posts on Medivizor

Ultra-hypofractionated radiotherapy leads to similar patient-reported quality of life outcomes versus conventionally fractionated radiotherapy for prostate cancer

Ultra-hypofractionated radiotherapy leads to similar patient-reported quality of life outcomes versus conventionally fractionated radiotherapy for prostate cancer

Posted by on Feb 27, 2021 in Prostate cancer | 0 comments

In a nutshell This study compared the patient-reported quality of life outcomes between conventionally fractionated radiation treatment (CFRT) and ultra-hypofractionated radiation treatment (UHFRT) in patients with localized prostate cancer. The data showed that both radiotherapy techniques led to similar long-term outcomes. Some background Radiation...

Read More

Can SOX and mFOLFOX6 chemotherapies be given without radiotherapy before surgery for advanced rectal cancer?

Can SOX and mFOLFOX6 chemotherapies be given without radiotherapy before surgery for advanced rectal cancer?

Posted by on Jan 31, 2021 in Colorectal cancer | 0 comments

In a nutshell This study evaluated the safety and effectiveness of two chemotherapy regimens (SOX and mFOLFOX6) before surgery for rectal cancer (RC) without radiotherapy. The study found that both regimens were safe and effective in these patients.   Some background RC is commonly treated with surgery to remove the tumor. Patients with...

Read More

Is radiosurgery in combination with other cancer therapies safe in patients with brain metastasis?

Is radiosurgery in combination with other cancer therapies safe in patients with brain metastasis?

Posted by on Jan 31, 2021 in Breast cancer | 0 comments

In a nutshell The aim of this study was to evaluate the safety of giving stereotactic radiosurgery (SRS) at the same time as other cancer treatments for patients who have brain metastasis. The study found that SRS given in combination with chemotherapy, immunotherapy, or targeted therapy was safe with low levels of side effects. Some background The...

Read More

Intensity-modulated radiation therapy with simultaneously integrated boost leads to shorter treatment time with similar outcomes as conventional radiotherapy after surgery for breast cancer

Intensity-modulated radiation therapy with simultaneously integrated boost leads to shorter treatment time with similar outcomes as conventional radiotherapy after surgery for breast cancer

Posted by on Jan 2, 2021 in Breast cancer | 0 comments

In a nutshell This study compared the effects of intensity-modulated radiation therapy (IMRT) with a simultaneously integrated boost (SIB) to conventional radiotherapy (CRT) with a sequential boost (SeqB) following breast-conserving surgery (BCS) in patients with breast cancer. The data showed that both radiotherapy techniques...

Read More

Evaluating long-term outcomes for proton therapy in men with localized prostate cancer.

Evaluating long-term outcomes for proton therapy in men with localized prostate cancer.

Posted by on Dec 31, 2020 in Prostate cancer | 0 comments

In a nutshell This study examined the long-term effectiveness and safety of proton therapy for localized prostate cancer. The data showed that proton therapy has favorable outcomes in these patients. Some background Localized prostate cancer (PCa) is a form of cancer that has not spread beyond the prostate gland. PCa can be treated by...

Read More

Does immune checkpoint therapy and radiotherapy combination improve response in treating brain metastasis from non-small cell lung cancer and melanoma?

Does immune checkpoint therapy and radiotherapy combination improve response in treating brain metastasis from non-small cell lung cancer and melanoma?

Posted by on Dec 30, 2020 in Lung cancer | 0 comments

In a nutshell The study evaluated the timing of radiotherapy (RT) and immune-checkpoint therapy (ICT) on the outcomes of patients with brain metastasis (BrM) resulting from melanoma and non-small cell lung cancer (NSCLC). The authors found that RT and ICT given at the same time may improve response and delay recurrence in these patients. Some background...

Read More

Comparing long-term outcomes of whole or partial breast irradiation after breast-conserving surgery

Comparing long-term outcomes of whole or partial breast irradiation after breast-conserving surgery

Posted by on Dec 13, 2020 in Breast cancer | 0 comments

In a nutshell This study compared whole breast irradiation (WBI) to partial breast irradiation (PBI) following breast-conserving surgery (BCS) in patients with low-risk breast cancer. The study showed similar survival between the 2 treatments, while PBI gave better cosmetic results. Some background Patients with low-risk breast...

Read More

Comparing whole-pelvis vs prostate only radiotherapy in patients with high-risk prostate cancer

Comparing whole-pelvis vs prostate only radiotherapy in patients with high-risk prostate cancer

Posted by on Dec 6, 2020 in Prostate cancer | 0 comments

In a nutshell This study compared the use of radiotherapy for prostate cancer in two areas: the prostate only, or the whole pelvis. The results showed that, for high-risk patients, radiotherapy of the whole pelvis improved patient outcomes. Some background For patients with medium or high-risk prostate cancer, the standard treatment is...

Read More

Comparing accelerated partial-breast irradiation and whole-breast irradiation in patients with early breast cancer.

Comparing accelerated partial-breast irradiation and whole-breast irradiation in patients with early breast cancer.

Posted by on Oct 10, 2020 in Breast cancer | 0 comments

In a nutshell This trial was carried out to assess the long-term results of external-beam accelerated partial-breast irradiation (APBI) intensity-modulated radiation therapy (IMRT) compared to whole-breast irradiation (WBI) in early-stage breast cancer (BC). The authors found that the 10-year recurrence of breast tumors was similar between the 2 methods,...

Read More

Ipilimumab and radiotherapy improves survival in patients with metastatic castration-resistant prostate cancer

Ipilimumab and radiotherapy improves survival in patients with metastatic castration-resistant prostate cancer

Posted by on Sep 30, 2020 in Prostate cancer | 0 comments

In a nutshell This trial was carried out to examine the effectiveness of radiotherapy followed by treatment with ipilimumab (Yervoy) in men with metastatic castrate-resistant prostate cancer  (mCRPC). The trial found that this treatment led to higher survival in these patients compared to radiotherapy followed by placebo. Some...

Read More